Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.
The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.
Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.
Cyperus rotundus oil is suggested as a natural treatment for androgenic alopecia, potentially inhibiting hair growth without affecting testosterone levels. The conversation questions its effectiveness and safety for scalp use.
The conversation discusses combining topical cetirizine with minoxidil for hair loss treatment and inquires about the safety and absorption through the skin, as well as the possibility of adding melatonin.
RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The user is looking for a PG-free solvent in the UK or EU to make their own pyrilutamide solution for hair loss and is currently using finasteride, considering minoxidil. They hope pyrilutamide will help stabilize their hair loss.
The conversation is about a user considering a hair transplant with BlueMagic Group and seeking real experiences and advice. Users suggest verifying who performs the surgery, looking for long-term results, and ensuring thorough communication before proceeding.
The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.
A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.
The conversation is about using RU58841 for hair loss after finasteride didn't work, with the user considering trying RU before minoxidil. Another user suggests trying oral dutasteride and oral minoxidil first.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.